ISOLATION AND DIFFERENTIATION OF A BIPHENOTYPIC CELL LINE FROM A PATIENT (PT) WITH MYELODYSPLASTIC SYNDROME (MEETING ABSTRACT)

Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

ISOLATION AND DIFFERENTIATION OF A BIPHENOTYPIC CELL LINE FROM A PATIENT (PT) WITH MYELODYSPLASTIC SYNDROME (MEETING ABSTRACT)

Proc Annu Meet Am Assoc Cancer Res; 33:A2100 1992. Unique Identifier : AIDSLINE ICDB/92684633
Banerjee R; Bekesi JG; Deak G; Strauchen J; Holland JF; Acs G; Mount Sinai Sch. of Medicine, Dept. of Biochemistry, New York, NY; 10029

Abstract: We isolated a cell line from the pleural exudate of a pt with myeloplastic syndrome exhibiting chronic myelomonocytic leukemia. After 3 generations, in vitro cells were mostly immature T cells (TCR gamma/delta+) containing myeloid marker CD15 but neither CD13 nor CD33. The cells are tumorigenic in nude mice, causing sc lymphoma indistinguishable from cutaneous tumors in the pt. A cell line established from the nude mouse tumor is identical to the original isolate: trisomy 21, CD4-, CD8-, class II Ag-, class I Ag+, CD15+, deoxynucleotide transferase (TdT+), transferrin receptor (CD71+) and progenitor antigens (CD34+). Rag 1 mRNA was detected in the cells. Immature T-cell markers (CD3-, TCR gamma/delta+) were expressed in 63%, and mature T-cell markers (CD3+, TCR alpha, beta+) were found in 10%. The addition of TPA downregulates PKC; cells differentiating in the T-cell lineage were 53% mature (CD3+, TCR alpha/beta+) and 34% immature (CD3-, TCR gamma/delta+). The combination of TPA and Br-cAMP treatment increases the proportion of cells with mature T-cell markers to 90%, all expressing IL-2 receptors (CD25). Transfection with HIV-1 genome cells produces infectious HIV-1 without cell lysis.

Keywords: Animal Antigens, CD/ANALYSIS Down Syndrome Human Mice Mice, Nude Myelodysplastic Syndromes/GENETICS/*IMMUNOLOGY Phenotype Proteins/GENETICS Receptors, Antigen, T-Cell/ANALYSIS RNA, Messenger/ANALYSIS Tetradecanoylphorbol Acetate/PHARMACOLOGY Tumor Cells, Cultured/DRUG EFFECTS 8-Bromo Cyclic Adenosine Monophosphate/PHARMACOLOGY ABSTRACT
921230
M92C5372

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .